Stock Research for MNOV

MNOV

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

MNOV Stock Chart & Research Data

The MNOV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MNOV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


MNOV Due diligence Resources & Stock Charts

The MNOV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MNOV Detailed Price Forecast - CNN Money CNN View MNOV Detailed Summary - Google Finance
Yahoo View MNOV Detailed Summary - Yahoo! Finance Zacks View MNOV Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View MNOV Trends & Analysis - Trade-Ideas Barrons View MNOV Major Holders - Barrons
NASDAQ View MNOV Call Transcripts - NASDAQ Seeking View MNOV Breaking News & Analysis - Seeking Alpha
Spotlight View MNOV Annual Report - CompanySpotlight.com OTC Report View MNOV OTC Short Report - OTCShortReport.com
TradeKing View MNOV Fundamentals - TradeKing Charts View MNOV SEC Filings - Bar Chart
WSJ View Historical Prices for MNOV - The WSJ Morningstar View Performance/Total Return for MNOV - Morningstar
MarketWatch View the Analyst Estimates for MNOV - MarketWatch CNBC View the Earnings History for MNOV - CNBC
StockMarketWatch View the MNOV Earnings - StockMarketWatch MacroAxis View MNOV Buy or Sell Recommendations - MacroAxis
Bullish View the MNOV Bullish Patterns - American Bulls Short Pains View MNOV Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View MNOV Stock Mentions - StockTwits PennyStocks View MNOV Stock Mentions - PennyStockTweets
Twitter View MNOV Stock Mentions - Twitter Invest Hub View MNOV Investment Forum News - Investor Hub
Yahoo View MNOV Stock Mentions - Yahoo! Message Board Seeking Alpha View MNOV Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for MNOV - SECform4.com Insider Cow View Insider Transactions for MNOV - Insider Cow
CNBC View MNOV Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MNOV - OTC Markets
Yahoo View Insider Transactions for MNOV - Yahoo! Finance NASDAQ View Institutional Holdings for MNOV - NASDAQ


Stock Charts

FinViz View MNOV Stock Insight & Charts - FinViz.com StockCharts View MNOV Investment Charts - StockCharts.com
BarChart View MNOV Stock Overview & Charts - BarChart Trading View View MNOV User Generated Charts - Trading View




Latest Financial News for MNOV


The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker
Posted on Friday October 05, 2018

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) Amarin Corporation plc (NASDAQ: AMRN ) BIOLINERX Ltd/S ...


MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma
Posted on Thursday October 04, 2018

LA JOLLA, Calif., Oct. 04, 2018 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock.


MNOV: Positive FDA Feedback on ALS Phase 3 Plan…
Posted on Friday September 28, 2018

On September 25, 2018, MediciNova, Inc. (MNOV) announced that the FDA provided positive feedback in regards to the company’s development plan for MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). The FDA did not raise any concerns with the safety of MN-166, only a single trial may be necessary if there is a statistically significant result when comparing MN-166 to placebo in a functional outcome (such as ALSFRS-R), and the agency would like to see a broad range of ALS patients with randomization stratified by baseline disease severity.


MediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS
Posted on Tuesday September 25, 2018

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received positive feedback from the FDA (U.S. Food and Drug Administration) regarding MediciNova’s Phase 3 clinical development plan for MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). If a single trial shows that MN-166 (ibudilast) has a statistically significant benefit compared to placebo in a measure of functional activity, such as ALSFRS-R, an additional trial may not be necessary. In order to detect the maximal potential benefit of MN-166 (ibudilast), FDA encouraged including a broad ALS population, with randomization that is stratified by baseline disease severity.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.